
Axsome Therapeutics, Inc.
AXSMNASDAQHealthcare● Active
$235.14
+$2.82(+1.21%)
Market Cap$12.1B
P/E Ratio—
52W High$242.41
52W Low$96.09
Axsome Therapeutics, Inc.(AXSM)· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · AXSM · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.32B | $0.32B | $0.39B | $0.20B | $0.09B |
| Net Receivables | $0.22B | $0.14B | $0.09B | $0.04B | $0.00B |
| Inventory | $0.03B | $0.02B | $0.02B | $0.00B | $0.00B |
| Total Current Assets | $0.59B | $0.49B | $0.50B | $0.25B | $0.09B |
| PP&E Net | $0.02B | $0.01B | $0.01B | $0.00B | $0.00B |
| Goodwill | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Intangible Assets | $0.04B | $0.05B | $0.05B | $0.06B | $0.00B |
| Total Assets | $0.69B | $0.57B | $0.59B | $0.33B | $0.09B |
| Liabilities | |||||
| Short-Term Debt | $0.07B | $0.00B | $0.00B | $0.00B | $0.00B |
| Accounts Payable | $0.07B | $0.07B | $0.04B | $0.04B | $0.01B |
| Total Current Liabilities | $0.38B | $0.23B | $0.14B | $0.10B | $0.02B |
| Long-Term Debt | $0.14B | $0.18B | $0.18B | $0.09B | $0.05B |
| Total Liabilities | $0.60B | $0.51B | $0.40B | $0.22B | $0.07B |
| Stockholders Equity | |||||
| Retained Earnings | ($1.31B) | ($1.12B) | ($0.84B) | ($0.60B) | ($0.41B) |
| Total Stockholders Equity | $0.09B | $0.06B | $0.19B | $0.11B | $0.02B |
| Total Liab & Equity(computed) | $0.69B | $0.57B | $0.59B | $0.33B | $0.09B |
| Debt Summary | |||||
| Total Debt | $0.24B | $0.19B | $0.19B | $0.09B | $0.05B |
| Net Debt | ($0.08B) | ($0.12B) | ($0.20B) | ($0.11B) | ($0.04B) |
数据来源:Financial Modeling Prep · 最后更新:2026-06-10 · USD · B
深入了解Axsome Therapeutics, Inc.
关于Axsome Therapeutics, Inc.(AXSM)资产负债表
Axsome Therapeutics, Inc.总资产$0.69B,现金及短期投资$0.32B,总负债$0.60B,总债务$0.24B,股东权益$0.09B。
常见问题
AXSM · 4 问Axsome Therapeutics, Inc.总债务$0.24B,净债务($0.08B)。
AXSM total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10